Merus to Participate in Upcoming Investor Conferences
31 8월 2023 - 9:00PM
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company
developing innovative, full-length multispecific antibodies
(Biclonics® and Triclonics®), today announced that Bill Lundberg,
M.D., President, Chief Executive Officer of Merus, will participate
in the following investor conferences:
- Citi's 2023 18th Annual BioPharma
Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m.
ET
- Morgan Stanley 21st Annual Global
Healthcare Conference: Wednesday, September 13 12:55-1:25 p.m.
ET
The webcasts of the presentations will be contemporaneously
available on the Investors page of the Company's website. Archived
presentations will also be available there for a limited time after
the event.
About MerusMerus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics, referred to
as Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website and twitter.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl
Merus NV (NASDAQ:MRUS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Merus NV (NASDAQ:MRUS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024